Trends in endemic of respiratory syncytial virus infection during COVID-19 pandemic and difficulty in obtaining optimal timing of palivizumab prophylaxis.

Publication date: Dec 10, 2024

The coronavirus disease (COVID-19) pandemic has affected the epidemiology of respiratory syncytial virus (RSV) infection. This study assessed whether or not palivizumab prophylaxis was appropriate during the COVID-19 pandemic. This prospective study included children

Concepts Keywords
Coronavirus COVID-19 pandemic
Covid endemic
Drugs optimal prophylaxis
Optimal palivizumab
Pandemic

Semantics

Type Source Name
disease MESH respiratory syncytial virus infection
disease MESH COVID-19 pandemic
drug DRUGBANK Palivizumab
pathway KEGG Coronavirus disease
disease MESH infection

Original Article

(Visited 1 times, 1 visits today)